ESR1 and breast cancer: Whereas we found a strong bias for tumors with normal CtIP/RBBP8 levels to be positive for ER and PR receptors (of 91.5% and 78%, respectively), breast cancers with no CtIP/RBBP8 staining had an almost equal distribution of HR-positive and HR-negative samples.